Navigation Links
OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for First Quarter 2013
Date:5/2/2013

f long-term obligations1,0881,084  Warrant liability1,9883,422  Long term liabilities4,0884,253  Stockholders' equity60,26566,207Total liabilities and stockholders' equity$
75,354$
82,016Conference Call Details OncoGenex will host a conference call at 4:30 p.m. Eastern Time today, Thursday, May 2, 2013, to provide a business update and discuss the first quarter 2013 results.

A live event will be available on the Investor Relations section of the OncoGenex Web site at www.OncoGenex.com. Alternatively, you may access the live conference call by dialing 877-606-1416 (U.S. & Canada) or 707-287-9313 (International). A replay of the webcast will be available approximately two hours after the call and will be archived for 90 days.

ABOUT ONCOGENEX
OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. (NYSE:  TEVA) have entered a global collaboration and license agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. OGX-427 is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development. More information is available at www.OncoGenex.com.

OncoGenex' Forward Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Li
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. OncoGenex Pharmaceuticals, Inc. Provides Update on Clinical Development Program and Reports Financial Results for Fourth Quarter and Year End 2012
2. OncoGenex Announces Plans for the Initiation of the Borealis-2 Clinical Trial Evaluating OGX-427 in Combination with Second-Line Therapy for Bladder Cancer
3. OncoGenex Announces Initiation of the Phase 3 "AFFINITY" Trial for Patients with Advanced Prostate Cancer
4. OncoGenex Pharmaceuticals, Inc. Reports Second Quarter and First-Half 2012 Financial Results and Reviews Clinical Development Highlights for Custirsen and OGX-427
5. Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company launch educational campaign about emerging science in type 2 diabetes
6. Cactus Ventures, Inc. Changes Name to Actinium Pharmaceuticals, Inc.
7. Omthera Pharmaceuticals, Inc. Announces Closing of Initial Public Offering
8. Avion Pharmaceuticals, LLC., announces further expansion of their Womens Health Sales Team
9. Omthera Pharmaceuticals, Inc. Announces Pricing of Initial Public Offering
10. Covis Pharmaceuticals, Inc Named US Distributor For Five Additional Products
11. Edison Pharmaceuticals, Inc. signs licensing agreement with Dainippon Sumitomo Pharma Co., Ltd. for development & commercialization of orphan mitochondrial and adult central nervous system disease drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... LONDON , July 11, 2014 /PRNewswire/ ... of visitors to Safety & Health Expo ... by the move to London ... senior management attending exhibition.     ... (Photo: http://photos.prnewswire.com/prnh/20140711/696892-a ) ...
(Date:7/10/2014)... , 11. Juli 2014  Dilon ... für die molekulare Bildgebung, einschließlich molekularer ... die CE-Zulassung für sein Navigator ® ... Dilon das Produkt jetzt europaweit vertreiben. ... Großteil der europäischen Länder ausgedehnt und ...
(Date:7/10/2014)... , July 10, 2014 Integrated Silicon Solution, ... advanced memory and analog IC solutions, today announced that ... July 24, 2014, at 7:00 a.m. Pacific Time (10:00 ... for the fiscal 2014 third quarter ended June 30, ... telephone, dial 1-888-556-4997 before 6:50 a.m. Pacific time on ...
Breaking Medicine Technology:UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 4Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2
... SAN DIEGO, March 30, 2011 Neurocrine Biosciences, Inc. (Nasdaq: ... and Chief Executive Officer of Neurocrine Biosciences, will be presenting ... City.   The live presentation takes place ... / 10:20 a.m. Pacific Time.  The presentation will be webcast ...
... AAIPharma Services Corp., a leading provider of ... its compendial raw materials testing group to a ... Wilmington, N.C., headquarters facility. The move follows a ... analytical testing business. (Logo:   http://photos.prnewswire.com/prnh/20110330/CG74146LOGO ...
Cached Medicine Technology:AAIPharma Services Announces Compendial Testing Facility Expansion 2
(Date:7/13/2014)... MarketsandMarkets recently conducted a study on ... 3D rendering; Layout and Animation; Image Reconstruction]: Global ... which analyzes and studies the major market drivers, ... Eastern Europe, Middle East and Africa, Asia-Pacific and ... landscape of the 3D imaging market, providing an ...
(Date:7/13/2014)... July 13, 2014 The Pearland, Texas location ... in age from four months to 12 years of age ... classes to birthday parties and Summer Camps, is now under ... Gym of Pearland after spending over six years at ... including Gym Director. , Berry has over ten years ...
(Date:7/13/2014)... 13, 2014 Recently, 2014QuinceaneraDresses.com, the ... unveiled its new range of gorgeous Quinceanera ... the demand for elegant Quinceanera outfits is huge. ... items. All the company’s newly released dresses are ... are all elegant and vivid. , It ...
(Date:7/13/2014)... 2014 Fadhits.com is popular among worldwide ... are extremely beautiful. Recently, the company has announced its ... 2014. What’s more, all these outfits are available at ... , Additionally, the supplier is now offering similar discounts ... dresses, it has many other designs for sale, including ...
(Date:7/13/2014)... COPENHAGEN, July 13, 2014 A decreased ability ... cognitive impairment and Alzheimer,s disease, while examinations of ... a protein associated with Alzheimer,s, in the brain, ... reported today at the Alzheimer,s Association International Conference ... of the studies, the decreased ability to identify ...
Breaking Medicine News(10 mins):Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 2Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 3Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 4Health News:The Little Gym of Pearland, TX Now Under New Ownership and Management 2Health News:2014QuinceaneraDresses.com Releases Its New Quinceanera Dresses 2Health News:Fadhits.com Announces a Special Offer on Elegant Quinceanera Dresses 2Health News:Smell and eye tests show potential to detect Alzheimer's early 2Health News:Smell and eye tests show potential to detect Alzheimer's early 3Health News:Smell and eye tests show potential to detect Alzheimer's early 4Health News:Smell and eye tests show potential to detect Alzheimer's early 5Health News:Smell and eye tests show potential to detect Alzheimer's early 6Health News:Smell and eye tests show potential to detect Alzheimer's early 7
... New findings show that treatment with a specific alpha ... for men with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). ... relaxing the muscles in the bladder neck and prostate. ... States, the EU and Japan to treat painful symptoms ...
... 11 (HealthDay News) -- Some men with enlarged prostate ... severe complications as a result, according to a new ... for enlarged prostate, the rate of men operated on ... the rate of discharges for men for enlarged prostate ...
... NJIT and UMDNJ have executed a license agreement with The ... on which a patent is pending. The tonometer ... Gordon Thomas, PhD, and Robert Fechtner, MD, director of the ... was a member of the research team. "We ...
... address a major new risk for the global supply ... the supply chain as pharmaceutical companies increasingly outsource the ... topic of the cover story in the current edition ... C&EN Senior Editor Rick Mullin explains that ...
... first time, researchers at McMaster University have conclusive evidence ... and behaviour. The findings are important because several ... are frequently associated with anxiety or depression. In addition ... as late onset autism, may be associated with an ...
... new study led by the University of Leicester has concluded ... in a doctor,s surgery helps to reduce emergency hospital admissions. ... Sciences at the University of Leicester revealed a correlation between ... hospital admissions. The research, published in Emergency Medical ...
Cached Medicine News:Health News:Experimental treatment offers relief from painful prostate condition 2Health News:Fewer Men Having Surgery to Treat Enlarged Prostate: Study 2Health News:NJIT and UMDNJ license personal tonometer technology for innovative glaucoma testing 2Health News:That anxiety may be in your gut, not in your head 2Health News:Patients who see preferred doctor less likely to go for emergency hospital admission 2
For the qualitative and semi-quantitative measurement of RF in human serum....
... The Newmarket Laboratories RPR kits use ... of lipid antigens, which will combine ... or plasma. The particles are suspended ... eliminate non - specific reactions. Positive ...
Rapid Plasma Reagin (RPR) set is a non-treponemal flocculation test that is,used for the qualitative and semi-quantitative determination of reagin,antibodies in serum or plasma from persons with syph...
... For use as a quality ... IgG antibody to Toxoplasma gondii ... rubella virus (rubella IgG), IgG ... and IgG antibody to herpes ...
Medicine Products: